Novartis shares slide after heart drug fails late-stage trial target
Novartis said its experimental medicine failed to reduce cardiovascular risk in a late-stage trial, sending shares down 3.2% in European morning trading Monday.
Story updates
08:27:19 AM UTC
SquawkNews
Novartis AG experienced a second trial setback within a week, as the Swiss pharmaceutical company's promising heart medication failed in a final-stage trial.A Bloomberg report said the drug, pelacarsen, did succeed in reducing levels of lipoprotein(a), a primarily genetic risk factor for cardiovasc…
By Adria Calatayud Novartis shares fell after the Swiss drugmaker said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial. 2% in European morning trading Monday, reducing year-to-date gains to 14%. The company said the late-stage…